

INSTITUTIONAL REVIEW BOARD

Application for Initial Protocol Submission

	FOR IRB OFFICE USE ONLY			
INSTRUCTIONS: Your application includes this form and all documents as defined in ARMC-IRB Guidelines for Principal Investigator of which you have been provided a copy. Answer all questions in the application form. Do not answer questions with "see protocol." Failure to properly complete this application and provide the supporting documents will delay the review and approval of your protocol by the ARMC-IRB. PART A – TITLE/ INVESTIGATOR/ COORI	Type of Review: ☐ Full Board ☐ Expedite ☐ Exempt IRB Protocol #:			
Title of Protocol:				
Principal Investigator -				
Name:	Hospital/Department:			
Phone Number:	Mailing Address:			
E-mail Address:				
Sub-Investigator(s) -				
If more than one, attach separate sheet listing all				
Name:	Hospital/Department:			
Phone Number:	•			
E-Mail Address:	Mailing Address:			
E-Wall Address:				
Sub-Investigator(s)				
Name:	Hospital/Department:			
Phone Number:	Mailing Address:			
E-Mail Address:				
Additional Sub-Investigators (see Attachment A)				
PART B – LEVEL OF RISK				
Level of Risk: Minimal Moderate High				

PART C – SOURCE OF FUNDING/ SPONSOR		
Indicate all applicable sources of funding and the sponsor		
Federal Sponsor Name:	,	
Commercial Sponsor Name:		
Foundation Sponsor Name:		
Other (specify) Name:		
□ No support		
но зирроге		
PART D – CONFLICT OF INTEREST		
PART D - CONFLICT OF INTEREST		
Does the principal investigator or any sub-ir	nvestigator (or any member of their	
immediate family) -		
a. Own or control any equity interest in any drug, device or technology involved in this research study?		
☐ Yes* [No	
b. Have a financial interest, direct or indirect, in any listed source of external support? \(\subseteq \text{Yes}^* \subseteq \text{No} \)		
c. Function as an advisor, employee, officer, director, or consultant for any listed		
commercial source of external support?		
Yes*	No	
*If yes, please attach detailed information to peri should be disclosed to potential subjects.	mit the IRB to determine if such involvement	
Should be dissibled to potential subjects.		
PART E - RECRUITMENT INFORMATION		
PART E - RECRUITMENT INFORMATION Subject Matter - Check all that apply		
Subject Matter - Check all that apply		
Subject Matter - Check all that apply Investigational New Drug IND #		
Subject Matter - Check all that apply Investigational New Drug Investigational New Device IDE #		
Subject Matter - Check all that apply Investigational New Drug Investigational New Device Marketed Drug, New Indication		
Subject Matter - Check all that apply Investigational New Drug Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month		
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes*	ns	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? *If yes, please attach a sample of the advertisem*	ns	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply	ns Years No ent.	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects	ns	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects	ns Years No ent.	
Subject Matter - Check all that apply Investigational New Drug Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects Patients	ns Years No ent.	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects Patients Classification - Check all that apply	ns	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects Patients Classification - Check all that apply Adults Physi	ns Years No ent.	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Patients Classification - Check all that apply Adults Minors (< 18yrs) Pregn Male	ns	
Subject Matter - Check all that apply Investigational New Drug IND # Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects Patients Classification - Check all that apply Adults Physi Minors (< 18yrs)	ns	
Subject Matter - Check all that apply Investigational New Drug Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Patients Classification - Check all that apply Adults Physi Minors (< 18yrs) Pregn Male Female Specify-	Number Age Range cally Handicapped Cognitively Impaired Comatose English Speaking: Prisoners * *Record Review Only	
Subject Matter - Check all that apply Investigational New Drug Investigational New Device IDE # Marketed Drug, New Indication Marketed Drug, Approved Indication Non-drug Study Duration of study: # Month Will you be advertising? Yes* *If yes, please attach a sample of the advertisem Subjects Involved - Check all that apply Subjects Healthy (normal) Subjects Patients Classification - Check all that apply Adults Physi Minors (< 18yrs) Pregn	Number Age Range cally Handicapped Cognitively Impaired Comatose English Speaking: Prisoners * *Record Review Only	

Source of subjects - Check all that apply		
☐ ARMC In-Patient ☐ ARMC Emergency Dept ☐ ARMC Out-Patients ☐ County/State Public Health		
Other (specify):		
PART F – CHECKLIST FOR APPLICATION - protocol submission contains the following:		
Study Objectives Degree of Human Subject Involvement		
☐ Background ☐ Informed Consent (as applicable)		
☐ Study Design ☐ Confidentiality statement		
PART G – APPROVALS: CLINICAL		
"I have read ARMC-IRB Investigator Guidelines and signed the Principal Investigator's Statement of Assurance"		
Principal Investigator's Signature Date		
"This protocol has been reviewed for scientific merit and has the academic endorsement of this department."		
Department Chair's Signature Date		
PART H – APPROVALS: RESOURCE UTILIZATION		
NURSING CARE: Will nurses be asked to provide study-associated care beyond the usual given for the patient's condition? (e.g., extra vital signs, administration of additional medications, more frequent monitoring, additional education)? Yes \(\subseteq \text{No} \subseteq \)		
If yes, please describe below, then provide appropriate signature:		
Chief Nursing Officer Approval Date:		
LABORATORY: Does the study require additional tests that would not be part of usual care for the patient's condition? Yes \(\square\) No \(\square\)		
· · · <u> </u>		

MEDICAL IMAGING: Does the study require added not be part of usual care for the patient's condition	
If yes, please describe below, then provide appro	opriate signature:
Medical Imaging Manager Approval Date:	
OTHER DEPARTMENT(S): Does the study require additional hospital resour provided? Yes \(\bigcup \) No \(\bigcup \)	: ces beyond that which is customarily
If yes, please describe below, then provide appro	opriate signature:
Administrative Approval:	Date:
CHIEF FINANCIAL OFFICER APPROVAL (REQU	IRED for all Sponsored Studies)
Have appropriate reimbursement arrangements Comments:	s been made? Yes No
Chief Financial Officer Approval:	Date

ARROWHEAD REGIONAL MEDICAL CENTER INSTITUTIONAL REVIEW BOARD

Principal Investigator Statement of Assurance

By signing below I agree/certify that:

- I have reviewed this protocol submission and agree to accept responsibility for the scientific conduct of this project.
- I will conduct this research in strict compliance with all Federal and/or State Regulations and ARMC-IRB standard operating procedures.
- I will ensure that all sub-investigators and other study personnel assisting in this research are fully educated as to the entire protocol and consent process as well as data and record keeping requirements.
- I will not enroll any individual into this research study until I have received <u>final</u> approval in writing from the ARMC-IRB or at any period of time where renewal approval has expired or enrollment has been suspended by either the ARMC-IRB or the study sponsor.
- I will submit any additions, corrections or modifications to the full protocol or the informed consent document to the ARMC-IRB for approval before implementing them.
- I will promptly report to the IRB, any serious adverse reactions, events, complications, or protocol deviations which may occur as a result of this study.
- I will respond promptly to all requests for information or materials from the ARMC-IRB or the IRB Office and will submit annual progress reports in a timely manner for ARMC-IRB renewal approval. It is understood *Exempt* approval expires one year from the date of approval.
- I will not enroll any individual into this research study until such time that I obtain his/her written informed consent, or, if applicable, that of his/her authorized representative.

Principal Investigator Name:		
Principal Investigator's Signature	Date	